| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 0 | 37.771 | 67.879 | 72.363 | 71.305 | 143.330 | 149.194 | 58.447 |
| Total Income - EUR | - | - | 3.284 | 158.640 | 293.012 | 595.922 | 325.919 | 1.570.688 | 943.799 | 502.528 |
| Total Expenses - EUR | - | - | 2.133 | 124.224 | 231.162 | 547.566 | 296.246 | 1.456.374 | 941.625 | 724.160 |
| Gross Profit/Loss - EUR | - | - | 1.150 | 34.416 | 61.850 | 48.356 | 29.673 | 114.314 | 2.174 | -221.632 |
| Net Profit/Loss - EUR | - | - | 1.118 | 34.351 | 61.762 | 48.356 | 29.673 | 113.164 | 1.158 | -221.632 |
| Employees | - | - | 1 | 2 | 3 | 5 | 5 | 7 | 6 | 6 |
Check the financial reports for the company - Compania Bionucis Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 734 | 268.776 | 655.077 | 1.276.280 | 1.336.336 | 2.242.497 | 2.511.300 | 2.360.628 |
| Current Assets | - | - | 5.203 | 2.111.962 | 2.054.143 | 1.380.982 | 1.218.231 | 692.666 | 250.675 | 159.073 |
| Inventories | - | - | 23 | 996 | 225.523 | 5.882 | 13.156 | 24.102 | 54.618 | 31.537 |
| Receivables | - | - | 0 | 1.711.600 | 1.633.466 | 1.344.279 | 1.175.425 | 644.550 | 142.123 | 109.858 |
| Cash | - | - | 5.180 | 399.366 | 195.154 | 30.821 | 29.651 | 24.014 | 53.934 | 17.679 |
| Shareholders Funds | - | - | 1.336 | 45.118 | 106.006 | 126.281 | 153.154 | 266.793 | 267.141 | 44.016 |
| Social Capital | - | - | 219 | 9.670 | 9.483 | 9.303 | 9.097 | 9.125 | 9.097 | 9.046 |
| Debts | - | - | 21.983 | 780.135 | 990.151 | 958.801 | 910.033 | 1.295.291 | 1.335.999 | 1.575.121 |
| Income in Advance | - | - | 0 | 1.556.510 | 1.638.712 | 1.591.420 | 1.510.297 | 1.392.054 | 1.177.751 | 919.375 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "125 - 125" | |||||||||
| CAEN Financial Year |
125
|
|||||||||
Comments - Compania Bionucis Srl